StemCell Therapy

DUBLIN, April 6, 2020 /PRNewswire/ -- The "Global Minimally Invasive Biopsy Technologies Market: Focus on Liquid Biopsy, Optical Biopsy, and Brush Biopsy, Pigmented Lesion Assays, and Breath Biopsy, Regulatory Scenario, Therapeutic Application, Competitive Landscape,18 Countries' Data - Analysis and Forecast, 2019-2030" report has been added to ResearchAndMarkets.com's offering.

According to the report, the global minimally invasive biopsy technologies market was valued at $924.8 million in 2018 and is anticipated to reach $4.03 billion by 2030. The global minimally invasive biopsy technologies market is expected to grow at a double-digit compound annual growth rate (CAGR) in the forecast period 2019-2030, aided primarily by the anticipated launch of novel minimally invasive biopsy technologies.

The rapidly growing incidences of cancer and other chronic inflammatory disorders are inciting the use of minimally invasive and real-time diagnostic methods for early detection. With better patient compliance and greater sensitivity, minimally invasive biopsy technologies such as liquid biopsy and optical biopsy are emerging as novel tools for the early detection and effective disease management. Additionally, several other technologies including brush biopsy, fine needle aspiration, breath biopsy, and pigmented lesion assays are considerably evolving to be used in the minimally invasive management of cancer.

The increasing adoption of targeted therapies and the growing prominence of the concept of personalized medicine is driving the adoption of minimally invasive biopsy technologies. The increasing adoption is further expected to bring down the cost and is expected to improve the patient access to these technologies.

North America is the leading contributor in the global minimally invasive biopsy technologies market and contributed approximately 62.06% to the global market value in 2018. This region is anticipated to grow at a CAGR of 11.25% during the forecast period 2019-2030 and to continue dominating the global market in 2030 as well. However, the European region is expected to grow at an impressive CAGR of 15.40% during the forecast period 2019-2030. The Asia-Pacific region contributed a share of 12.41% to the global market and is anticipated to grow at a CAGR of 14.65% during the forecast period 2019-2030.

Research Highlights

Optical biopsy expected to witness an impressive CAGR of 15.77% during the forecast period 2019-2030. Moreover, in terms of therapeutic application, prostate cancer is expected to witness an impressive growth at a CAGR of 14.97% during the forecast period 2019-2030.

Liquid biopsy is currently the largest shareholder in the global minimally invasive biopsy technologies market. This market dominance is largely attributed to the worldwide availability of a significant number of liquid biopsy technologies.

This market intelligence report provides a multi-dimensional view of the global minimally invasive biopsy technologies market in terms of market size and growth potential. This research report aims at answering various aspects of the global minimally invasive biopsy technologies market with the help of key factors driving the market, restraints that can possibly inhibit the overall growth of the market, and the current growth opportunities that are going to shape the future trajectory of the market expansion.

Furthermore, the competitive landscape chapter in the report explicates the competitive nature of the global market and enables the reader to get acquainted with the recent market activities, such as product launches and approvals, partnerships, collaborations, business expansions, as well as mergers and acquisitions. The research report provides a comprehensive analysis of the product sales, manufacturers, service providers, and trend analysis by segment, and growth share analysis by region. Additionally, the report provides a comprehensive attractive analysis and opportunity analysis for the entire global minimally invasive biopsy technologies market for 2018 and 2030.

This report is a meticulous compilation of the research of about 65 players in the market ecosystem and draws upon insights from in-depth interviews with the key opinion leaders of 9 leading companies, market participants, and vendors. The report also comprises 15 detailed company profiles including that of Abcodia Ltd., Adaptive Biotechnologies, Biocept, Inc., Caliber Imaging & Diagnostics, Chronix Biomedical, DermTech, F. Hoffmann-La Roche Ltd, Guardant Health, Inc., Mauna Kea Technologies, Myriad Genetics, NeoGenomics Laboratories, Inc., Owlstone Medical Ltd, QIAGEN, Thermo Fisher Scientific, and Veracyte, Inc.

The answers to the following key questions can be derived from this report:

Key Topics Covered

Executive Summary

1 Product Definition1.1 Inclusions and Exclusions

2 Research Scope2.1 Scope of Work2.2 Key Questions Answered in the Report

3 Research Methodology3.1 Global Minimally Invasive Biopsy Technologies Market: Research Methodology3.1.1 Primary Data Sources3.1.2 Secondary Data Sources3.1.3 Selection Criteria for Company Profiles

4 Industry Analysis4.1 Industry Ecosystem4.2 Regulatory Framework and Government Initiatives4.2.1 Liquid Biopsy: Regulatory Framework4.2.1.1 Liquid Biopsy: Regulations in the U.S.4.2.1.2 Liquid Biopsy: Regulations in Other Countries4.2.2 Optical Biopsy and Other Technologies: Regulatory Framework4.2.2.1 Optical Biopsy and Other Technologies: Regulations in the U.S.4.2.2.2 Optical Biopsy and Other Technologies: Regulations in Europe4.2.2.3 Optical Biopsy and Other Technologies: Regulations in Other Countries4.3 Patent Analysis4.3.1 Liquid Biopsy: Patent Analysis4.3.2 Optical Biopsy: Patent Analysis4.4 Physician's Perception

5 Competitive Landscape5.1 Key strategies and Developments5.1.1 Partnerships, Alliances, and Business Expansions5.1.2 New Offerings5.1.3 Funding Activities5.1.4 Procurement and Sales Agreements5.1.5 Regulatory and Legal Developments5.1.6 Mergers and Acquisitions5.2 Market Share Analysis5.2.1 Market Share Analysis: Global Liquid Biopsy Market5.2.2 Market Share Analysis: Global Optical Biopsy Market5.2.3 Market Share Analysis: Global Other Technologies Market5.3 Growth Share Analysis5.3.1 Growth Share Matrix (by Technology)5.3.2 Growth Share Matrix (by Therapeutic Application)5.3.3 Growth Share Matrix (by Region)

6 Global Minimally Invasive Biopsy Technologies Market, 2018-20306.1 Assumptions and Limitations6.2 Key Findings and Opportunity Assessment6.3 Global Minimally Invasive Biopsy Technologies, Market Scenario6.3.1 Global Minimally Invasive Biopsy Technologies Market Size and Forecast (2018-2030)6.3.2 Market Dynamics6.3.2.1 Overview6.3.2.2 Impact Analysis6.3.2.3 Market Drivers6.3.2.3.1 Rising Global Burden of Cancer6.3.2.3.2 Increasing Number of Cross-Industry Collaborations6.3.2.3.3 Growing Prominence of Precision Medicine6.3.2.4 Market Restraints6.3.2.4.1 Uncertain Regulatory Requirements6.3.2.4.2 Lack of Favorable Reimbursement Policies6.3.2.4.3 Technical Challenges Associated with the Analysis of Circulating Biomarkers6.3.2.5 Market Opportunities6.3.2.5.1 Business Expansion in Emerging Economies6.3.2.5.2 Integration of Artificial Intelligence (AI)6.3.2.5.3 Rising Number of Initiatives by the Government6.4 Market Estimation Method

7 Global Minimally Invasive Biopsy Technologies Market, by Technology, 2018-20307.1 Overview7.2 Global Liquid Biopsy Market Scenario, 2018-20307.2.1 Principle and Advantages of Liquid Biopsy7.2.2 Key Findings and Opportunity Assessment7.2.3 Global Liquid Biopsy Market, Market Size and Forecast (2018-2030)7.2.3.1 Market Dynamics7.2.3.1.1 Impact Analysis7.2.3.1.2 Market Drivers7.2.3.1.2.1 Increasing Demand for Liquid Biopsy Tests7.2.3.1.2.2 Recent Product Launches and Approvals7.2.3.1.2.3 Strong Pipeline7.2.3.1.3 Market Restraints7.2.3.1.3.1 Uncertain Regulatory Requirements7.2.3.1.3.2 Lack of Adequate Reimbursement7.2.4 Global Liquid Biopsy Market Segmentation7.2.4.1 Global Liquid Biopsy Market (by Product), 2018-20307.2.4.1.1 Overview7.2.4.1.2 Tests7.2.4.1.3 Kits and Consumables7.2.4.1.4 Instruments7.2.4.2 Global Liquid Biopsy Market, by Circulating Biomarker, Market Size and Forecast (2018-2030)7.2.4.2.1 Overview7.2.4.2.2 Circulating Tumor DNA (ctDNA)7.2.4.2.3 Circulating Tumor Cells (CTCs)7.2.4.2.4 Cell-Free DNA (cfDNA)7.2.4.2.5 Extracellular Vesicles and Others7.2.4.3 Global Liquid Biopsy Market, by Clinical Application, Market Size and Forecast (2018-2030)7.2.4.3.1 Overview7.2.4.3.2 Treatment Monitoring7.2.4.3.3 Prognosis and Recurrence Monitoring7.2.4.3.4 Treatment Selection7.2.4.3.5 Diagnosis and Screening7.2.4.4 Global Liquid Biopsy Market, by Therapeutic Application, Market Size and Forecast (2018-2030)7.2.4.4.1 Overview7.2.4.4.2 Lung Cancer7.2.4.4.3 Breast Cancer7.2.4.4.4 Prostate Cancer7.2.4.4.5 Colorectal Cancer7.2.4.4.6 Blood Cancer7.2.4.4.7 Other Types of Cancer7.2.4.4.8 Non-Oncology Applications7.3 Global Optical Biopsy Market Scenario, 2018-20307.3.1 Principle and Advantages of Optical Biopsy7.3.2 Key Findings and Opportunity Assessment7.3.3 Global Optical Biopsy Market, Market Size and Forecast (2018-2030)7.3.3.1 Market Dynamics7.3.3.1.1 Impact Analysis7.3.3.1.2 Market Drivers7.3.3.1.2.1 Recent Product Launches and Approvals7.3.3.1.2.2 Significant Number of Funding and Investments7.3.3.1.2.3 Anticipated Product Launches7.3.3.1.3 Market Restraints7.3.3.1.3.1 Lack of Favorable Reimbursement7.3.3.1.3.2 Stringent Regulatory Guidelines7.3.4 Global Optical Biopsy Market (by Therapeutic Application), 2018-20307.3.4.1 Overview7.3.4.2 Oncology7.3.4.3 Non-Oncology Applications7.4 Global Other Technologies Market Scenario, 2018-20307.4.1 Overview7.4.2 Key Findings and Opportunity Assessment7.4.3 Global Other Technologies Market, Market Size and Forecast (2018-2030)7.4.3.1 Market Dynamics7.4.3.1.1 Impact Analysis7.4.3.1.2 Market Drivers7.4.3.1.2.1 Ongoing Strategic Collaborations and M&A Activities7.4.3.1.2.2 Strong Product Pipeline7.4.3.1.3 Market Restraints7.4.3.1.3.1 Poor Reimbursement Scenario7.4.3.1.3.2 Limited Scope of Expansion in Emerging Economies7.4.4 Global Other Technologies Market, (by Therapeutic Application)7.4.4.1 Overview7.4.4.2 Lung Cancer7.4.4.3 Melanoma7.4.4.4 Thyroid Cancer7.4.4.5 Non-Oncology Applications

8 Global Minimally Invasive Biopsy Technologies Market, (by Region), 2018-20308.1 Overview and Key Findings8.2 North America8.3 Europe8.4 Asia-Pacific8.5 Latin America and the Middle East8.6 Rest-of-the-World

9 Company Profiles9.1 Abcodia Ltd.9.2 Adaptive Biotechnologies9.3 Biocept, Inc.9.4 Caliber Imaging & Diagnostics9.5 Chronix Biomedical9.6 DermTech9.7 F. Hoffmann-La Roche Ltd.9.8 Guardant Health, Inc.9.9 Mauna Kea Technologies9.10 Myriad Genetics9.11 NeoGenomics Laboratories, Inc.9.12 Owlstone Medical Ltd.9.13 QIAGEN9.14 Thermo Fisher Scientific9.15 Veracyte, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/3128v2

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-minimally-invasive-biopsy-technologies-markets-2019-2030---a-4-billion-opportunity-with-focus-on-liquid-biopsy-optical-biopsy-and-brush-biopsy-pigmented-lesion-assays-and-breath-biopsy-301035982.html

SOURCE Research and Markets

Read more:
Global Minimally Invasive Biopsy Technologies Markets, 2019-2030 - A $4+ Billion Opportunity with Focus on Liquid Biopsy, Optical Biopsy, and Brush...

This entry was posted on April 6, 2020 at 6:44 pm and is filed under Personalized Medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |